Newborn screening for congenital toxoplasmosis: Feasible, but benefits are not established

Archives of Disease in Childhood

Volumn 91, Issue 8, 2006, Pages 629-632

  Gilbert, R ^a   Dezateux, C ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; BIOLOGICAL MARKER; COTRIMOXAZOLE; IMMUNOGLOBULIN M ANTIBODY; PYRIMETHAMINE; SPIRAMYCIN; SULFONAMIDE;

ANXIETY; CONGENITAL TOXOPLASMOSIS; FEASIBILITY STUDY; FOLLOW UP; HUMAN; NEUTROPENIA; NEWBORN SCREENING; PERINATAL PERIOD; PREGNANCY TERMINATION; PRENATAL DIAGNOSIS; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; TOXOPLASMA GONDII;

FEMALE; HUMANS; INFANT, NEWBORN; NEONATAL SCREENING; PREGNANCY; PREGNANCY COMPLICATIONS, PARASITIC; TOXOPLASMOSIS, CONGENITAL;

EID: 33746919573     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/adc.2006.094870     Document Type: Review

References (43)

1. Schmidt DR, Hogh B, Andersen O, et al. The national neonatal screening programme for congenital toxoplasmosis in Denmark: results from the initial four years, 1999-2002. Arch Dis Child 2006;91:661-5.
2. Neto EC, Rubin R, Schulte J, et al. Newborn screening for congenital infectious diseases. Emera Infect Dis 2004;10:1068-73.
3. Guerina NG, Hsu HW, Meissner HC, et al. Neonatal serologic screening and early treatment for congenital Toxoplasma gondii infection. The New England Regional Toxoplasma Working Group. N Engl J Med 1994;330:1858-63.
4. Paul M, Petersen E, Pawlowski ZS, et al. Neonatal screening for congenital toxoplasmosis in the Poznan region of Poland by analysis of Toxoplasma gondii-specific IgM antibodies eluted from filter paper blood spots. Pediatr Infect Dis J 2000;19:30-6.
5. Vela-Amieva M, Canedo-Solares I, Gutierrez-Castrellon P, et al. Short report: neonatal screening pilot study of Toxoplasma gondii congenital infection in Mexico. Am J Trop Med Hyg 2005;72:142-4.
6. Neto EC, Anele E, Rubim R, et al. High prevalence of congenital toxoplasmosis in Brazil estimated in a 3-year prospective neonatal screening study. Int J Epidemiol 2000;29:941-7.
7. Petersen E, Pollak A, Reiter-Owona I. Recent trends in research on congenital toxoplasmosis. Int J Parasitol 2001;31:115-44.
8. Evengard B, Petterson K, Engman M-L, et al. Low incidence of toxoplasma infection during pregnancy and in newborns in Sweden. Epidemiol Infect 2001;127:121-7.
9. National Newborn Screening Programme Republic of Ireland. http: www.nnsp.ie/disorders_tested/toxoplasmosis_02.html. 2006.
10. Paul M, Petersen E, Szczapa J. Prevalence of congenital Toxoplasma gondii infection among newborns from the Poznan region of Poland: validation of a new combined enzyme immunoassay for Toxoplasma gondii-specific immunoglobulin A and immunoglobulin M antibodies. J Clin Microbiol 2001;39:1912-16.
11. Binquet C, Wallon M, Quantin C, et al. Prognostic factors for the long-term development of ocular lesions in 327 children with congenital toxoplasmosis. Epidemiol Infect 2003;131:1157-68.
12. Gras L, Gilbert RE, Ades AE, et al. Effect of prenatal treatment on the risk of intracranial and ocular lesions in children with congenital toxoplasmosis. Int J Epidemiol 2001;30:1309-30.
13. Wallon M, Kodjikian L, Binquet C, et al. Long-term ocular prognosis in 327 children with congenital toxoplasmosis. Pediatrics 2004;113:1567-72.
14. Lebech M, Andersen O, Christensen NC, et al. Feasibility of neonatal screening for toxoplasma infection in the absence of prenatal treatment. Lancet 1999;353:1834-7.
15. Naessens A, Jenum PA, Pollak A, et al. Diagnosis of congenital toxoplasmosis in the neonatal period: a multicenter evaluation. J Pediatr 1999;135:714-19.
16. Wallon M, Dunn D, Slimani D, et al. Diagnosis of congenital toxoplasmosis at birth: what is the value of testing for IgM and IgA? Eur J Pediatr 1999;158:645-9.
17. Pinon JM, Chemla C, Villena I, et al. Early neonatal diagnosis of congenital toxoplasmosis: value of comparative enzyme-linked immunofiltration assay immunological profiles and anti-Toxoplasma gondii immunoglobulin M (IgM) or IgA immunocapture and implications for postnatal therapeutic strategies. J Clin Microbiol 1996;34:579-83.
18. Working Group on Toxoplasma Infection in Pregnancy. http: rms.nelh.nhs.uk/screening/viewResource.asp?categoryID = 2009&dg = 107&uri = http%3A, and libraries.nelh.nhs.uk/common/resources/%3Fid%3D56186. Antenatal and newborn screening for toxoplasmosis. Antenatal Subcommittee of the National Screening Committee. 2001. http://www.nelh.nhs.uk/screening/ antenatal_pps/Toxo_NSC.pdf.
19. Buffolano W, Sagliocca L, Fratta D, et al. Prenatal toxoplasmosis screening in Campania region, Italy. Ital J Gynaecol Obstet 1994;6:70-4.
20. Berrebi A, Kobuch WE, Bessieres MH, et al. Termination of pregnancy for maternal toxoplasmosis. Lancet 1994;344:36-9.
21. Conyn-van-Spaedonck MAE. Prevention of congenital toxoplasmosis in the Netherlands (thesis). National Institute of Public Health and Environmental Protection (Netherlands), ISBN 90-9004179-6, 1991.
22. Gilbert R, Dunn D, Wallon M, et al. Ecological comparison of the risks of mother-to-child transmission and clinical manifestations of congenital toxoplasmosis according to prenatal treatment protocol. Epidemiol Infect 2001;127:113-20.
23. Gilbert RE, See SE, Jones LV, et al. Antibiotics for treating and preventing toxoplasma retinocnoroiditis. The Cochrane Library, 2002;issue 3.
24. Silveira C, Belfort R Jr, Muccioli C, et al. The effect of long-term intermittent trimethoprim/sulfamethoxazole treatment on recurrences of toxoplasmic retinochoroiditis. Am J Ophthalmol 2002;134:41-6.
25. Holland GN. Ocular toxoplasmosis: a global reassessment. Part II: disease manifestations and management. Am J Ophthalmol 2004;137:1-17.
26. Ajzenberg D, Banuls AL, Su C, et al. Genetic diversity, clonality and sexuality in Toxoplasma gondii. Int J Parasitol 2004;34:1185-96.
27. Gras L, Wallon M, Pollak A, et al. Association between prenatal treatment and clinical manifestations of congenital toxoplasmosis in infancy: a cohort study in 13 European centers. Acta Paediatr Scand 2005;94:1-12.
28. Denkers EY, Gazzinelli RT. Regulation and function of T-cell-mediated immunity during Toxoplasma gondii infection. Clin Microbiol Rev 1998;11:569-88.
29. Roberts F, Mets MB, Ferguson DJ, et al. Histopathological features of ocular toxoplasmosis in the fetus and infant. Arch Ophthalmol 2001;119:51-8.
30. Hartup C, Johnson JD, Holliman RE. The investigation of toxoplasma infection associated with pregnancy. J Infect 1997;35:47-54.
31. Thulliez P. Screening programme for congenital toxoplasmosis in France. Scand J Infect Dis Suppl 1992;84:43-5.
32. Fricker HH, Pelloux H, Muet F, et al. Prenatal diagnosis of congenital toxoplasmosis: comparative value of fetal blood and amniotic fluid using serological techniques and cultures. Prenatal Diagn 1997;17:831-5.
33. Gilbert R, Gras L. Effect of timing and type of treatment on the risk of mother to child transmission of Toxoplasma gondii. BJOG 2003;110:112-20.
34. Binquet C, Wallon M, Metral P, et al. [Toxoplasmosis seroconversion in pregnant women. The differing attitudes in France]. Presse Med 2004;33:775-9.
35. Kieffer F, Thulliez P, Brezin A, et al. Treatment of subclinical congenital toxoplasmosis by sulfadiazine and pyrimetriamine continuously during 1 year: apropos of 46 cases. Arch Pediatr 2002;9:7-13.
36. Derouin F, Jacqz-Aigrain E, Thulliez P, et al. Cotrimoxazole for prenatal treatment of congenital toxoplasmosis? Parasitol Today 2000;16:254-6.
37. Freeman K, Salt A, Prusa A, et al. Association between congenital toxoplasmosis and parent-reported developmental outcomes, concerns and impairments, in 3 year old children. Biomed Central Pediatrics 2005;5:23.
38. Gilbert RE, Tan HK, Cliffe S, et al. Symptomatic toxoplasma infection due to congenital and postnatally acquired infection. Arch Dis Child (in press).
39. Gilbert RE, Stanford MR. Is ocular toxoplasmosis caused by prenatal or postnatal infection? Br J Ophthalmol 2000;84:224-6.
40. Holland GN. Ocular toxoplasmosis: a global reassessment. Part I: epidemiology and course of disease. Am J Ophthalmol 2003;136:973-88.
41. Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ 2001;10:779-87.
42. Claxton K. The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. J Health Econ 1999;18:341-64.
43. Thulliez P, Romand S. Prenatal screening and prevention of congenital toxoplasmosis in France. In: Amboise-Thomas P, Petersen E, eds. Congenital toxoplasmosis: scientific background, clinical management and control. Paris: Springer-Verlag, 2000:293-8.